1-8 of 8
Patricia Galván
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial

Maria Vidal, Claudette Falato, Tomás Pascual, Rodrigo Sanchez-Bayona, Montserrat Muñoz-Mateu, Isaac Cebrecos, Xavier Gonzalez-Farré, Tomás Cortadellas, Mireia Margelí Vila, Miguel A. Luna, Christian Siso, Kepa Amillano, Patricia Galván, Milana A. Bergamino, Juan M. Ferrero-Cafiero, Fernando Salvador, Alejandra Espinosa Guerrero, Laia Pare, Esther Sanfeliu, Aleix Prat, Meritxell Bellet
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-2460
Published: 18 February 2025
View article titled, Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
Open the PDF for Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial in another window
Includes: Supplementary data
Journal Articles

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel R. Borrego, Patricia Galván, Joel S. Parker, Wesley Buckingham, Charles M. Perou, Patricia Villagrasa, Jose A. Guerrero, Miguel Sampayo-Cordero, Mario Mancino, Aleix Prat, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4123–4130.
https://doi.org/10.1158/1078-0432.CCR-24-0464
Published: 13 September 2024
View article titled, HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Open the PDF for HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial in another window
Includes: Supplementary data
Journal Articles

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C. Pavlick, Patricia Galvan, Brent Rexer, Andres Forero-Torres, Rita Nanda, Anna M. Storniolo, Ian E. Krop, Matthew P. Goetz, Julie R. Nangia, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Susan G. Hilsenbeck, Aleix Prat, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3101–3109.
https://doi.org/10.1158/1078-0432.CCR-22-3753
Published: 15 August 2023
View article titled, A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Open the PDF for A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarneri, Javier Cortes, Patricia Villagrasa, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3116–3125.
https://doi.org/10.1158/1078-0432.CCR-20-4102
Published: 01 June 2021
View article titled, Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy
Open the PDF for Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy in another window
Includes: Supplementary data
Journal Articles

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan Christoph Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston, Eva Ciruelos, Joel S. Parker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6141–6148.
https://doi.org/10.1158/1078-0432.CCR-20-2793
Published: 01 December 2020
View article titled, A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Open the PDF for A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaño, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-20-0844
Published: 13 November 2020
View article titled, Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Open the PDF for Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial in another window
Includes: Supplementary data
Journal Articles

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Aleix Prat, Patricia Galván, Begoña Jimenez, Wesley Buckingham, H. Arthur Jeiranian, Carl Schaper, Maria Vidal, Martina Álvarez, Sherley Díaz, Catherine Ellis, Paolo Nuciforo, Sean Ferree, Nuria Ribelles, Barbara Adamo, Santiago Ramón y Cajal, Vicente Peg, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 560–566.
https://doi.org/10.1158/1078-0432.CCR-15-0630
Published: 31 January 2016
View article titled, Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Open the PDF for Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay in another window
Includes: Supplementary data
Journal Articles

A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

Idoia Garcia, Gemma Mayol, José Ríos, Gema Domenech, Nai-Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galvan, Carmen de Torres, Jaume Mora, Cinzia Lavarino
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2012–2023.
https://doi.org/10.1158/1078-0432.CCR-11-2483
Published: 01 April 2012
View article titled, A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Open the PDF for A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma in another window
Includes: Supplementary data